FDAsafety guidance84% confidence
October - December 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Xeljanz; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Supporting Context
- Therapeutic area
- Immunology · JAK Inhibitors
- Sub-indication
- General
Related signal: FDA Updates Boxed Warnings for JAK Inhibitors Due to Serious Risks